Coherus Oncology, Inc. — Form 8-K
Filed August 5, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 42/100
What the filing says
Coherus Oncology reported Q2 2026 LOQTORZI (toripalimab) net revenue of $13.6M, up 15% vs Q1 2026 and 37% vs Q2 2025 ($10.0M), driven by volume growth in nasopharyngeal carcinoma. However, the company burned $119.9M cash in H1 2026 vs $72.5M in H1 2025 (65% increase). Cash and equivalents fell to $105.3M as of June 30, 2026 (vs $172.1M Dec 31, 2025), after adjusting for TSA items. Operating losses narrowed: H1 2026 net loss $70.3M vs H1 2025 $92.3M, though absolute cash outflow accelerated. Pipeline programs (tagmokitug, casdozokitug) are in Phase 1b/2a with data expected H2 2026.
Why this rating
LOQTORZI growth is positive, but rapid cash depletion (36% reduction in 6 months) and 15-month runway at current burn rates present material risk for $81.9M market cap company. Pipeline is early-stage. Event is material operationally but not transformational.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.